GANX Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 28.53%, SMA50 5.24%, SMA200 17.95%). The stock’s 14-day RSI is 61.29 (firm momentum), while the ATR of 0.21 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -42.86% below its high and over 75.89% above its low. Average 10-day trading volume of 583.00 thousand shares is below the 3-month average of 694.46 thousand, indicating normal recent market interest.

Gain Therapeutics, Inc. has 35.95 million shares outstanding. The public float is 29.58 million shares, elevated short interest at 0.73% of float. This equals 243.00 thousand shares. The short ratio is 0.82 days. Institutional investors hold 10.96% of the float. Insiders own 3.64%. RICHMAN ERIC I holds 277.63 thousand shares, Islam Khalid has 50.00 thousand shares and Riley Jeffrey Scott has 30.00 thousand shares.

Gain Therapeutics, Inc. generated EPS of -$0.64 over the past year. Five-year average earnings growth is -37.02%. Wall Street analysts project EPS growth of 2.3% annually over the next five years. The latest quarter delivered EPS of -$0.11. The next quarter is forecast at -$0.14. Next year's EPS is expected at $23.12. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 7 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $9.00 to $6.00. The high target offers 376.19% upside. The low target suggests 217.46% downside. The mean target is $7.86. This offers 315.87% upside. Gain Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended March 26, 2026, missed forecasts by -21.43%. The prior quarter beat by 0.66%. Over the last six quarters, Apple has recorded several small beats. These include -26.09% in November 14, 2024.

Gain Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.61. This means the shares are trading above this model’s fair value.

Gain Therapeutics, Inc. (NASDAQ:GANX) closed at $1.90 USD, gaining $0.02 (1.06%) from the previous close of $1.88. The stock is currently mid-range between its 52-week high and low $1.41 and $4.34. With a market capitalization of about $81.04 million, Gain Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.11). Key stats such as the average daily volume over the past year has been around 695.07 thousand shares, in line with its 52-week average. Headquartered in Bethesda, MD, Gain Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Gene Mack, the company employs approximately 23 people and listed since March 19, 2021. Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding.

Gain Therapeutics, Inc. trades at a P/E ratio of -3.07, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.34 trading at moderately above to book value. The P/FCF stands at -4.34, also below market averages.

Our AI price prediction model suggests that Gain Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.17%, with price expected at $1.83 by May 14, 2026, within a range of $1.65 to $2.05 3-Month Outlook: Projected fall of -71.43%, reaching $0.54 by July 29, 2026, with a range of $0.38 to $0.64. 1-Year Outlook: Projected gain of 270.37%, with price at $7.00 by April 30, 2027, within a range of $0.00 to $13.96.

Gain Therapeutics, Inc. (NASDAQ:GANX) shares are down -38.2% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Gain Therapeutics, Inc. trading at a premium to the broader market with a P/E of -3.07. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $8.80, suggesting 365.61% upside. Our AI forecast model points to short-term weakness (-3.17% over two weeks), a medium-term fall (-71.43% over three months), and a longer-term gain (270.37% over one year), with expected trading ranges indicating moderate volatility.